CompoAtlas

Duofilm Liquid

Originaltext auf Französisch.

In Kanada zugelassenes natürliches Gesundheitsprodukt

Die Analyse oraler Dosen ist ohne einen nachgewiesenen ausschließlich oralen Verabreichungsweg nicht anwendbar.

Zusammensetzung

Arzneilicher Inhaltsstoff und QuelleJe Dosiseinheit laut Quelle
Acide lactique16,7 %

Nicht arzneiliche Inhaltsstoffe

Flexible collodion

In Kanada empfohlene Dosen

BevölkerungsgruppeAlterMenge pro EinnahmeHäufigkeit
Sous-population S/ONon précisée1 Goutte(s)24 heures

In Kanada zugelassene Verwendungen

For the removal of common warts.

Originaltext auf Englisch.

Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.

Warnhinweise in Kanada

Cautions and Warnings : DUOFILM® is for external use only. DUOFILM® is extremely flammable and should be kept away from fire or flame. Keep bottle tightly capped when not in use. Store at controlled room temperature away from heat. Patients should be advised not to inhale the vapour. DUOFILM® may cause eye irritation. Avoid contact with eyes and other mucous membranes. In case of accidental contact with the eyes or other mucous membranes, flush with water for 15 minutes. If discomfort persists, patients should be advised to contact a physician. Avoid exposure to healthy skin. DUOFILM® may cause skin irritation. If undue skin irritation develops, treatment should be discontinued and patients should be advised to contact a physician or pharmacist. Consider alternative treatments if warts cover a large area of the body (more than 5 cm²) due to the potential risk of salicylate toxicity. DUOFILM® is not recommended in patients with peripheral neuropathy except under the supervision of a physician. Oral salicylates taken during or immediately after a viral illness have been associated with Reye's syndrome and hence there is a theoretical risk with topical salicylates. Therefore, do not use in children or teenagers during or immediately after chickenpox, influenza, or other viral infections. It has been reported that salicylates are excreted via breast milk. Patients should be advised to consult a health care physician if discomfort persists. Keep out of the sight and reach of children. Pregnancy and Lactation Pregnancy The safety of DUOFILM® during human pregnancy has not been established. Studies in animals given salicylic acid orally demonstrated embryo-toxicity at high doses. DUOFILM® is not recommended during pregnancy. Lactation Salicylates are excreted in human milk. DUOFILM® is not recommended during lactation. If used or administered during lactation, care should be taken to avoid contact with the breast area in order to avoid accidental ingestion by the infant.

Originaltext auf Englisch.

Known Adverse Reactions : Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency. Frequencies are defined as: very common (greater than and or equal to 1/10), common (greater than and or equal to 1/100 to less than 1/10), uncommon (greater than and or equal to 1/1000 to less than 1/100) rare (greater than and or equal to 1/10000 to less than 1/1000) and very rare (less than 1/10000). Clinical Trial Data Immune system disorders Common: Rash Skin and subcutaneous tissue disorders Very common: Application site reaction, pruritus, burning sensation, erythema, scaling, dryness Common: Skin hypertrophy Post-marketing data Immune system disorders Rare: Application site hypersensitivity including inflammation Skin and subcutaneous tissue disorders Rare: Application site pain and irritation. Application site discoloration/skin discoloration. Exposure to healthy skin can lead to application site blistering and skin exfoliation. Allergic dermatitis. Interactions DUOFILM® may increase the absorption of other topically applied medicines. Therefore, concomitant use of DUOFILM® and other topical medicines on the treated area should be avoided.

Originaltext auf Englisch.

Produktdaten

Inhaber
Haleon US Holdings LLC
NPN oder DIN-HM
00370576
Status
Lizenz nicht aktiv
Lizenzdatum
30. November 2009
Überarbeitungsdatum
21. Februar 2017
Form
Solution semblabe au collodion.
Verabreichungsweg
Topique
Art des Antrags
DIN de transition

Quelle

Amtlicher Health-Canada-Eintrag, Zulassung 00370576

Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Originaltext auf Englisch.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Originaltext auf Französisch.

Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.

Liste in der amtlichen Überarbeitung vom (Register: Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise).

Verpackung fotografieren

Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.

Liste aus dem Jahr 2017. Fotografieren Sie die Verpackung, um Änderungen zu prüfen.

Eingabetaste zum Analysieren, Umschalt+Eingabetaste für eine neue Zeile